Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 7/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | LDHB | P07195 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632773 | 0.94 | SMN1; SMN2 (0.46) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1631308 | 0.92 | GBA1 (0.39) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1631445 | 0.89 | GBA1 (0.41) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1632360 | 0.88 | GBA1 (0.41) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1631138 | 0.88 | PIK3CD (0.39) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1630280 | 0.88 | GBA1 (0.40) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1632598 | 0.88 | GBA1 (0.41) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1629670 | 0.87 | GBA1 (0.37) | SMN1; SMN2F2GBA1PIK3CDJAK3 | |
| SCHEMBL1629838 | 0.86 | GBA1 (0.40) | F2GBA1JAK3KMT2AALDH1A1 | |
| SCHEMBL1631782 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2F2GBA1JAK3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | SMN1; SMN2 328/4885F2 2588/4885GBA1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.